Matthew A. Spear - Aug 20, 2021 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Aug 20, 2021
Transactions value $
-$29,854
Form type
4
Date filed
8/24/2021, 05:12 PM
Previous filing
Jul 30, 2021
Next filing
Sep 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Options Exercise $5.29K +4K +9.64% $1.32 45.5K Aug 20, 2021 Direct
transaction PSTX Common Stock Sale -$35.1K -4K -8.79% $8.79 41.5K Aug 20, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Stock Option (Right to Buy) Options Exercise $0 -4K -4.22% $0.00 90.9K Aug 20, 2021 Common Stock 4K $1.32 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock option is fully vested and exercisable.